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A percutaneous aortic device for cerebral embolic
protection during cardiovascular intervention
Jeffrey P. Carpenter, MD,a Judith T. Carpenter, MD,a Armando Tellez, MD,b John G. Webb, MD,c
Geng Hua Yi, MD,b and Juan F. Granada, MD,b Camden, NJ; Orangeburg, NY; and Vancouver, British
Columbia, Canada
Background: Embolic stroke is a major cause of morbidity in aortic and cardiac interventional procedures. Although
cerebral embolic protection devices have been developed for carotid interventions and for open heart surgery, a
percutaneous device for cerebral embolic protection during aortic and cardiac interventions would be desirable.
Methods: The Embrella Embolic Deflector (Embrella Cardiovascular Inc, Wayne, Pa) is a percutaneously placed embolic
protection device, inserted by a 6F access in the pig’s right forelimb, and deployed in the aorta, covering the
brachiocephalic vessel origins. The device functions by deflecting embolic debris downstream in the aortic circulation. A
swine model (n  3) was developed for testing the deployment, retrieval, and efficacy of the device using a carotid
filtration circuit for collection of emboli. Human atheromatous material was prepared as embolization particles with
diameters between 150 and 600 m. Deflection efficiency of the device was calculated by comparing numbers of embolic
particles in the carotid circulation during protected and unprotected injections.
Results: The device was reliably deployed, positioned, and retrieved (n  24). There was no significant drop in blood
pressure across the membrane of the device to suggest reduction of cerebral blood flow. The device did not become
occluded by embolic debris despite an embolic load many times that encountered in the clinical situation. Particles
entering the carotid circulation after aortic injection of emboli were reduced from 19% of total (unprotected) to 1.3%
(protected, P< .0001), with 98.7% of all injected particles being deflected downstream. There was no evidence of arterial
injury related to the device found at necropsy.
Conclusion: The Embrella Embolic Deflector performs safely and reliably in the swine model of human atheroembolism.
It effectively deflects almost all emboli downstream, away from the carotid circulation. The deflector shows promise as an
aortic embolic protection device and merits further investigation. (J Vasc Surg 2011;54:174-81.)
Clinical Relevance: Embolic stroke plagues cardiovascular interventions involving manipulation of the heart and
proximal aorta. An embolic protection device for use during these interventions which can be percutaneously placed is
desirable in order to reduce the cerebrovascular risk of these interventions.
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pThe Embrella Embolic Deflector (Embrella Cardiovas-
cular Inc, Wayne, Pa) was designed to meet the need for
embolic protection during procedures on the heart or
involving the passage of catheters over the aortic arch.
Emboli may arise from manipulation of the heart valves or
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174tria in addition to the aortic surface. The need for protec-
ion from these embolic events has become more acute
ecause these procedures have become more frequent and
ndovascular solutions are being devised and used for an
ver-increasing number and variety of cardiac and vascular
roblems. In this setting, unlike that of open surgery, there
s no opportunity to “wash out” or “flush” emboli, resulting
n serious neurologic events that range from life-threatening
trokes to “asymptomatic infarcts,” lesions found on diffu-
ion-weighted magnetic resonance imaging with no appar-
nt clinical correlate. Procedures that involve manipulating
atheters around the vicinities of the aortic root, particu-
arly in the setting of significant atherosclerotic disease,
ould benefit from protection against carotid emboli.
Even small catheters used for cardiac catheterization have
een shown to scrape debris off the aortic arch and have an
ssociated risk of emboli to the brain.1One study showed that
n 1000 consecutive percutaneous cardiac revascularization
rocedures, the guiding catheter had scraped debris from the
orta in50%.2 A recent animal study showed that emboli are
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Volume 54, Number 1 Carpenter et al 175generated by passage of catheters across even a noncalcified
aorta.3 A clinical study showed cerebral emboli were detected
in 100% of patients undergoing cardiac catheterization by
transcranial Doppler, although all patients were asymptom-
atic.4Onenotable studyof101patientswithaortic stenosiswho
underwent retrograde catheterization of the aortic valve showed
focal diffusion-imaging abnormalities after the procedure in a
pattern consistent with acute cerebral embolic events in 22% of
patients, and 3 (3%) had clinically apparent neurologic deficits.5
Balloon aortic valvuloplasty (BAV) has become more
prevalent and is now used as a step before placement of
percutaneous valves and as a palliative measure for patients
who are not candidates for transcatheter aortic valve implan-
tation (TAVI).6 Valvuloplasty involves passage of large cath-
eters across the aortic arch, as well as balloon fracture and
manipulation of sclerotic aortic valves. Thoracic endovascular
aortic repair (TEVAR) also involves the passage of large cath-
eters through the aortic arch, and embolic strokes have been
seen in an average of 2.9% of cases, with a range of 0% to 19%
in different studies according the definition.7 The stroke rate
forTEVAR increased dramatically to 27.7%when the thoracic
aorta repair extended up to the level of the proximal descend-
ing aorta in patients with a history of stroke, suggesting that
passage of wires and then large catheters (up to 25F) through
this part of the aorta led to a “snowplow” effect of emboli
towards the head vessels.8 Risk of emboli correlated with a
finding of mobile emboli as well as to the location and extent
of atherosclerotic disease in the ascending aorta.9 Percutane-
ous aortic valve replacement involves manipulation of the
aorta and the aortic valve in patients at risk for atheroma.
Stroke rates for TAVI are between 4% and 11%.10,11
The major risk of emboli is that they will enter the
brain. Downstream end organs have redundant blood sup-
plies and can tolerate emboli of a size that would cause
Fig 1. The Embrella Embolic Deflector is made of nitinol and a
porous membrane (100-m diameter pores). It is percutaneously
placed via a 6F sheath inserted in the right forelimb, with its tip
positioned at the brachiocephalic artery ostium. The device is
deployed by pushing it out the end of the sheath and is retrieved by
retracting it back into the sheath.stroke or even death in the cerebral circulation. Presently, 1ardiac catheterization, percutaneous interventions, BAV,
AVI, and TEVAR are all performed without embolic
rotection, with the risk of cerebral emboli considered
navoidable and the risk of other downstream emboli
onsidered acceptable. Embolic protection devices cur-
ently in use, which are able to protect both carotid arteries
rom embolic material, span the entire aortic lumen, such as
he Embol-X device (Embol-X, Inc, Mountain View,
alif). Used only in open cardiac procedures, this device
ollected particulate matter in 97% of cases.12
ETHODS
Device. The Embrella Embolic Deflector (Fig 1) cere-
ral embolic protection device consists of a nitinol frame
nd porous membrane with 100-m pores that allow con-
inuous blood flow through the device while deflecting
mbolic debris. The deployed device covers the ostia of the
nnominate and left common carotid arteries, deflecting
ebris downstream in the aorta. It is inserted percutane-
usly through a 6F sheath placed in the right forelimb.
Animal model. Three female or castrated Domestic
orkshire swine (Sus scropha sp) weighing 56 to 63 kg
ere used for the experiments, performed under good
aboratory practice protocol. One intramuscular musca-
inic anticholinergic dose (glycopyrrolate, concentration
.2 mg/mL; dosage, 0.005-0.02 mg/kg) was given
efore the preprocedure. Induction was achieved with a
apid acting general anesthetic consisting of tiletamine
nd zolazepam (Telazol [Fort Dodge Animal Health,
ort Dodge, Iowa]; concentration, 100 mg/mL; dos-
ge, 2-5 mg/kg). Animals underwent endotracheal in-
ubation and were maintained with 1% to 3% of contin-
ous inhalation of isoflurane. As an acute procedure,
nalgesics and antibiotics were not indicated as part of
he protocol. The animals were heparinized with 5000 to
ig 2. Animalmodel:Thepig’s snout is to theextremeright.Cannulae
replaced into thecarotids and returnblood through the jugular vein.All
arotid circulation blood flow passes through cartridges containing
hangeable 78-mfilter disks for collection of emboli.0,000 U intravenous bolus to maintain an activated
c
w
b
d
j
1
I
b
t
fi
j
t
r
w
6
t
f
p
r
c
c
s
t
6
a
T
t
d
s
i
i
s
t
o
s
m
T
f
e
e
d
c
e
c
i
m
t
p
r
(
i
c
device deployed, and (D) at the time of device retrieval.
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July 2011176 Carpenter et allotting time 300 seconds and had been pretreated
ith aspirin (650 mg) and clopidogrel (300 mg) 1 day
efore the procedure and aspirin (325 mg) and clopi-
ogrel (150 mg) on the day of the procedure.
The left and right carotid arteries and the right
ugular vein were surgically exposed and cannulated with
0F arterial perfusion cannulae (Edwards Lifesciences,
rvine, Calif; Fig 2). A circuit was created that routed the
lood flow through silicone tubing from each carotid
hrough a cartridge containing a changeable 78-m pore
ltration disk (Fig 3) and returned that blood to the
ugular vein. Thus, all carotid blood flow passed through
he filtration system.
For purposes of blood pressure monitoring and arte-
iography, a 6F sheath (Terumo Inc, Ann Arbor, Mich)
as percutaneously placed in the right femoral artery. A
F hydrophilically coated sheath (Cook Inc, Blooming-
on, Ind) was percutaneously inserted into the right
orelimb artery using a Seldinger technique with its tip
ositioned at the ostium of the innominate artery. Arte-
ial pressure measurements were simultaneously re-
orded from the innominate and femoral sheaths.
An aortogram was performed with a calibrated pigtail
atheter (Angiodynamics Inc, Queensbury, NY) to mea-
ure aortic dimensions and view branching anatomy of
he great vessels (Fig 4).
The Embrella Embolic Deflector was inserted via the
F forelimb sheath, which had been inserted over a wire
nd positioned at the ostium of the innominate artery.
hen, the device was pushed out into the aorta allowing
he device to self-expand. The device was deployed un-
er fluoroscopic guidance (Fig 5, online only) and was
ecured into position covering the ostia of both the
nnominate and left common carotid arteries. Position-
ng was confirmed by contrast injection of the forelimb
heath, demonstrating that the device was seated along
he greater curvature of the aortic arch covering the ostia
f the innominate and left common carotid arteries. The
heath was maintained in the innominate artery for re-
oval after the device had been retrieved back into it.
he device was retrieved by withdrawing it into the
orelimb sheath and then removing it.
At the conclusion of the experiments, the animal was
uthanized by injection of potassium chloride and the aorta
xamined for evidence of injury (Fig 6).
Embolization. Human atheromata derived from ca-
aver aortas was harvested. Atherosclerotic material was
ut into pieces and ground in a standard tissue homog-
nizer. The resulting material was filtered using several
ertified laboratory sieves resulting in emboli sizes rang-
ng from 150 to 300 m (stained with blue tissue
arking dye) and 300 to 600 m (stained with orange
issue marking dye). The resulting particles were sus-
ended in saline, and an aliquot was studied, which
evealed a particle concentration of 143 particles/mL
98 blue, 45 orange). A 4-mL aliquot of this solution was
njected into the ascending aorta via a standard 6F pigtailFig 3. A, The filters in the carotid shunt circuit are approximately
the size of a dime, with one for each carotid (left and right). They
collect all emboli passing through the carotid circulation. The emboli
are made of human atheroma and are color coded by size; blue are
150-300 m and orange are 300-600 m. Filters collected emboli
from (B) unprotected injections, (C) injections with the deflectoratheter, positioned at the level of the aortic valve, and
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Volume 54, Number 1 Carpenter et al 177followed by a flush of 30 mL of normal saline solution to
clear all emboli from the catheter and tubing.
Emboli collected in the carotid filtration cartridges were
counted under a dissecting microscope and recorded, as well
as the number of emboli residing on the Embrella Embolic
Deflector membrane upon retrieval. Carotid filtration car-
tridges (Fig 3)were removed for examination 15 seconds after
injection of emboli either with (test, Fig 3, C) or without
(control, Fig 3, B) the Embrella Embolic Deflector in place.
Fig 4. Porcine sizing aortogram.
Fig 6. Aortic arch at necropsy showed no evidence of vessel
trauma related to the device upon gross inspection. The ostia of the
brachiocephalic and left subclavian arteries are seen. Embolic
stroke plagues cardiovascular interventions involvingmanipulation
of the heart and proximal aorta. An embolic protection device for
use during these interventions, which can be percutaneously
placed, is desirable in order to reduce the cerebrovascular risk of
these interventions.The 15 seconds allowed for several cardiac cycles to eject all of che emboli out of the aortic arch. In addition, to determine
ow many emboli were shed during retrieval of the Embrella
mbolic Deflector, the carotid filtration cartridges were ex-
mined again 15 seconds after the retrieval step (Fig 3, D).
ontrol injections were performed before every test injection.
Statistics. The total number of downstream-de-
ected particles was determined to be equal to the total
umber of particles injected (Pi), (injection volume 
article concentration) less the sum of the number of
articles captured in the carotid filtration system and
etained on the device.
Deflection efficiency (DE) was determined by compar-
son of the number of particles captured by the carotid
lters during an unprotected injection (Pc, control) to the
umber of particles captured by the carotid filters during
rotected injections (test). The total number of particles
scaping the Embrella Embolic Deflector to enter the
arotid arteries was determined as the sum of those noted in
he filters after emboli injection with the device deployed
Pd) and after the retrieval step (Pr). Thus, carotid deflec-
ion efficiency (%) was calculated as: DEcarotid {1 [(Pd
r)/Pc]}  100.
Total deflection efficiency was also calculated, indicat-
ng the percent of total injected particles deflected down-
tream: DEtotal  {1  [(Pd  Pr)/Pi]}  100.
The t test was used for comparison of means.
ESULTS
We tested 24 devices in three animals weighing a
ean 59 kg (range, 56-63 kg). The aortic arch diameters
aried from 24.7 to 28.3 mm. The devices were success-
ully deployed and retrieved in every case and reliably
overed the ostia of the innominate and left common
ration marks are at 1-cm intervals.arotid arteries upon initial deployment, without the
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contrast injection.
No significant pressure gradients (5% mean arterial
pressure difference between forelimb and femoral
sheaths) were noted at any time across any of the de-
ployed devices, as measured continuously by the femoral
and innominate sheath transducers (Fig 7).
Deflection studies. A baseline aortic injection of
embolic particles without the device in place resulted in
Fig 7. Femoral-forelimb pressure differential was measu
The innominate sheath tip was on the distal side of flow a
gradients across the device were observed.
Table. Deflection efficiencya
Animal Devices Injection type Total carotid filters, No
1 1–8 Control 87  14.6
Deployed 7.0  4.2
Retrieved 6.0  3.2
2 9–16 Control 140  11.5
Deployed 2.9  2.2
Retrieved 0.1  0.4
3 17–24 Control 103.4  24.2
Deployed 7.4  5.9
Retrieved 2.6  6.2
Overall
Data are presented as mean  standard deviation.
aHuman atheromatous emboli were injected in the ascending aorta, with
collected in a carotid filtration circuit.19% of particles (range, 15%-24%) traveling to the ca- potid circulation and 81% (range, 76-85%) traveling
ownstream in the aortic circulation. With the device in
lace, the percentage of particles deflected downstream
ncreased from a mean of 81% to 98.7% (P  .0029;
able).
The overall DE for carotid emboli was 91.1% (range,
7.0%-100%). The average number of particles passing
hrough the carotid filters was reduced from a baseline
unprotected) average of 110 to 8.7 particles when
ontinuously at the femoral and innominate sheath tips.
the Embrella embolic deflector. No significant pressure
Deflection efficiency, %
Device membrane retained, No. Carotid Total
85.1  5.9 97.7  0.9
56.6  27.1
97.9  1.6 99.5  3.7
3.3  2.3
90.3  6.7 98.3  12.2
9.5  14.0
91.1  7.3 98.5  9.2
yed) and without (control) the Embrella embolic deflector in place, andred c
cross.rotected by the device (P  .0001). There was no
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small (150-300 m) and large (300-600 m) particles.
The devices did not become overwhelmed or oc-
cluded by embolic load despite injections of large
amounts of embolic material, as evidenced by the ab-
sence of any change in pressure gradient across the
devices after injection. The porous membrane of the
devices retained relatively few particles (mean, 23; range,
0-101), deflecting most particles downstream. The sur-
face area of the deployed device was 10.84 cm2, and the
maximum surface area of adherent emboli was far less
than 1% of the total device surface area.
Gross inspection of the aorta at necropsy revealed no
signs of injury at the site of device deployment despite
multiple deployments in most animals (Fig 6).
DISCUSSION
Aortic and cardiac interventional procedures are as-
sociated with a significant risk of embolic stroke. Trans-
catheter aortic valve procedures have a reported stroke
rate of 4% to 11%10,11 and stroke represents the most
prevalent major morbidity associated with this new tech-
nology. Thoracic endovascular aneurysm repair is also
associated with a significant stroke risk.7,8 These strokes
are largely attributable to the dislodgement of emboli
that enter the cerebrovascular circulation. A device that
provides embolic protections during aortic and cardiac
interventions would significantly enable the further de-
velopment of these minimally invasive procedures.
The Embrella Embolic Deflector was easily deployed
and retrieved using familiar techniques through a percu-
taneously placed 6F right arm sheath. The device was
deployed within the aorta without significant interaction
with the aortic walls. The device self-aligned in the aorta
to cover the ostia of the brachiocephalic vessels. The
positioning and sealing of the device were easily con-
firmed by contrast injection of the delivery sheath. Be-
cause the device enters the aorta through the right
subclavian artery, it is “out of the way” of index proce-
dures that will chiefly use femoral artery access routes to
the aorta or heart. Its low profile against the greater
curvature of the aorta allowed unimpeded passage of
catheters and wires used in the study. The device per-
formed reliably in deployment, sealing, and retrieval in
all of our studies. Inspection of the aortas showed no
evidence of injury after eight deployments and retrievals.
The pigs in this study had nonatherosclerotic aortas,
which is a limitation of the study.
Traditional distal embolic protection devices rely
upon filters to capture emboli. A main difference with
this technique is that it provides embolic protection by
deflection rather than collection of emboli. Emboli ric-
ochet off of the device towards downstream aortic beds,
which are much more redundant and forgiving in their
blood supply and branching patterns than the cerebro-
vascular circulation. In the case of a very large embolus
capable of causing significant injury to a downstream
organ, the effect would likely be less devastating than a atroke caused by the same embolus and the patient could
otentially be treated with embolectomy. The 100-m
ores of the device exclude dangerous emboli yet permit
risk blood flow. The pore size was chosen based on the
ore size of commercially available embolic protection
evices, which have been shown to decrease the number
f clinically dangerous emboli.
No significant pressure gradients across the mem-
rane were noted when comparing femoral with innom-
nate artery pressures. The device is continuously
purged” by the cardiac output washing the surface
lean of emboli. At a maximum, 1% of the surface area
as covered by emboli adherent to the membrane of the
evice despite the delivery of embolic loads many times
reater than those encountered in the clinical situation.
his feature offers a significant advantage over tradi-
ional cerebral protection devices with filter-capture pro-
ection schemes that can become occluded by trapped
mboli limiting flow through to the brain.
The device diverted an average of 98.7% of the total
elivered embolic load downstream, away from the ca-
otid circulation. Looking specifically at the dangerous
mboli destined for the carotid arteries, the deflection
fficiency for carotid emboli was 91.1% compared with
ontrols. The latter number compares the number of
mboli noted in the carotid filters for an unprotected
njection vs a protected injection. This compares favor-
bly with other distal embolic protection devices. Several
uthors have performed in vitro testing of filter capture
fficiency.
Siewiorek et al13 embolized resin microspheres in a
ow model simulating the carotid circulation with ca-
otid cerebral protection devices deployed. They found a
apture efficiency of 95% for the FilterWire EZ (Boston
cientific, Natick Mass), 92% for the Accunet (Guidant
orp, Indianapolis, Ind), and 62% for the Emboshield
Abbott, Abbott Park, Ill).
Order et al,14 in a similar in vitro carotid model using
icrospheres, obtained capture efficiencies of 84%
TRAP; Microvena, White Bear Lake, Minn), 94% (Fil-
erWire EX; Boston Scientific) and 70% (Angioguard;
ordis, Miami Lakes, Fla).
Rapp et al,15 in a carotid flow model of protected
arotid angioplasty using intact excised human carotid
ndarterectomy specimens, found low capture efficiency
or distal protection devices when confronted with hu-
an atheromatous emboli. Capture efficiencies ranging
rom only 13.7% to 28% were documented for the Spider
ev3 Endovascular, Inc, Plymouth, Minn), FilterWire
Z, Accunet, Angioguard, and Emboshield, suggesting
hat atheromatous emboli present a greater challenge
han do microspheres. The observed “leak path” for
hese carotid embolic protection devices was around the
ealing edge of the device where the wire frame circum-
erentially contacts the vessel wall. The pore size of the
evice could be changed if this were deemed clinically
eneficial. Devices with pore sizes down to 40 m allow
dequate flow in the human bloodstream.
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device was high, it was not perfect. Possibly some emboli
pass around the sealing edge of the device rather than
through its pores. The device seals by conforming its
nitinol wire perimeter with the surface of the aorta. The
pulsatile turbulent flow in the arch might allow an em-
bolus to slip past the edge. The ability to seal well on an
irregular surface in the presence of a diseased arch re-
mains to be determined. Some emboli also entered the
carotid circulation during the retrieval phase of the pro-
cedure. Suggested mechanisms might include release of
emboli trapped between the sealing edge of the device
and the aorta at the time of retrieval or shedding of
emboli from the surface of the membrane during re-
trieval. The latter situation may be benefited by a “down-
stream” resheathing of the device.
The safety of the device was demonstrated by its reliable
deployment and retrieval and absence of any gross evidence
of vessel trauma at necropsy. Histologic examination in a
future study will provide a more detailed analysis. In addi-
tion, the device did not significantly reduce cerebral blood
flow while deployed.
The animal model proved useful for study of the
device. Pigs weighing 50 kg had aortic dimensions
comparable to humans. The branching anatomy of the
porcine arch provides a single brachiocephalic vessel
from which the left and right carotids and the right
subclavian artery derive. The second arch vessel is a
separate left subclavian artery. This two-vessel arch anat-
omy is seen in 15% of humans with the bovine arch
variation. Measurement of blood pressure at the tip of
the brachiocephalic sheath provides sampling of the
entire carotid circulation due to the common origin of
both carotid arteries. The human atheromatous emboli
preparation provided for a more “realistic” challenge of
physiologic irregularly shaped embolic material than
would be possible with resin microspheres. These em-
bolic particles performed reliably and reproducibly in our
experiments and we believe they are an excellent surro-
gate for the clinical situation of plaque-related emboli-
zation during interventional procedures.
The carotid shunt circuit provided high flow reliably.
Initial attempts to route flow from each carotid through the
filtration circuit and back to the distal ipsilateral carotid
failed to provide adequate flow due to intractable vaso-
spasm in the distal carotids. By returning blood flow to the
jugular vein, a reliable shunt circuit was established with
high flow. Of the embolic particles injected during control
experiments, 19% entered the carotid circulation with this
shunt circuit in place, which is consistent with a physiologic
distribution of cerebral blood flow as a percentage of car-
diac output.
CONCLUSIONS
The Embrella Embolic Deflector performs safely and
reliably in a swine model of aortic embolization of ath-
eromatous debris. It deflects 98.7% of aortic emboli
downstream, away from the carotid circulation. It doesot impede cerebral blood flow or become overwhelmed
y adherent emboli, nor does it cause apparent injury to
he aorta. Further investigation of the device and its
pplications to interventional aortic and cardiac proce-
ures is warranted.
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July 2011181.e1 Carpenter et alFig 5. (online only). A, Fluoroscopic appearance of the de-
ployed Embrella Embolic Deflector. The pigtail catheter is posi-
tioned for emboli injection. B, Injection of the brachiocephalic via
the forelimb sheath reveals a “seal” behind the device, and opacifies
